ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
Feng Ji(Guangxi Medical University), Guo‐Dong Lu(Guangxi Medical University)
Cited by 161
Related Papers
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
|Acta Pharmacologica Sinica|2020|300
Fatty acid activation in carcinogenesis and cancer development: Essential roles of long‑chain acyl‑CoA synthetases (Review)
|Oncology Letters|2018|154
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy
|Experimental & Molecular Medicine|2022|35